Cardio3 BioSciences Avoiding Binary Event Risks By Adding CAR-T Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgium’s Cardio3 BioSciences aims to apply its experience in developing cell therapies, principally a stem cell therapy for heart failure that is in Phase III trials, to other therapeutic areas, reducing its exposure to the risks of a single success or failure event.